Answers are grounded in this paper and cite their sources.
INTRODUCTION: Although the Decipher Genomic Classifier (GC) improves risk stratification beyond standard National Comprehensive Cancer Network (NCCN) risk groups, distinct clinical discordance exists between them. Herein, we interrogate specific adverse molecular features (AMFs) associated with genomic upgrading/downgrading relative to clinical risk and evaluate their overall long-term prognostic impact on treated patients. MATERIALS AND METHODS: The specific prevalence of four separate AMFs (TP53 status, PTEN inactivation, lower androgen receptor [AR] activity, and RB1 loss) was evaluated across GC and NCCN risk groups using biopsy data from 287,145 patients. Prognostic associations with distant metastasis (DM) were fully assessed in 15,109 patients with NCCN high and very high-risk disease. RESULTS: Decipher re-classified 21% of NCCN low and favorable intermediate-risk patients as high risk, while 33% of NCCN high-risk patients were GC-lower risk. AMF prevalence associated more strongly with GC than NCCN groups. TP53 mutant-like status, PTEN inactivation, and lower AR activity were associated with NCCN-GC discordance. Within the study cohort, a high GC score was associated with significantly increased risk of DM; AMFs independently predicted DM. Patients with at least one adverse AMF and a GC score >0.60 had a predicted 5-year DM probability of 17-25%, compared to 5% for those with favorable molecular profiles and a GC score ≤0.60. CONCLUSIONS: Individual AMFs are associated with the discordance between NCCN and GC risk classifications. In patients with NCCN high-risk disease, the GC score serves as a primary prognostic driver, while AMF profiling provides additive risk stratification within specific clinical GC strata.
No takes yet. Share an insight, caveat, or question.
Zelefsky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: